Nizar J. Bahlis, MD, discusses daratumumab (Darzalex) plus lenalidomide (Revlimid) and dexamethasone in newly diagnosed multiple myeloma.
Nizar J. Bahlis, MD, associate professor at University of Calgary, Alberta, Canada, discusses daratumumab (Darzalex) plus lenalidomide (Revlimid) and dexamethasone (Rd) in newly diagnosed multiple myeloma (NDMM).
In the phase III MAIA trial, patients who enrolled were ineligible for transplant and treated with a combination of daratumumab plus lenalidomide and dexamethasone, which proved to be superior to Rd alone. With a median follow-up of 28.0 months, the median progression-free survival of the daratumumab arm was not reached compared with 31.9 months (HR, 0.56; P <.001) in the control arm. These results represent a new standard of care, says Bahlis.
The 2019 ASH Annual Meeting included a presentation of the LYNX trial, which is looking at re-treatment with daratumumab in combination with carfilzomib (Kyprolis) and dexamethasone in relapsed/refractory myeloma. While daratumumab is being used in the frontline setting, it is hopeful that with future studies data will show that daratumumab can be reused in a subsequent line of therapy, concludes Bahlis.